AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03386032 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Cream
Description: Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
Study NCT04508452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
Study NCT02239497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral block by ultrasound and neurostimulation
Study NCT02239497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
Study NCT00518635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin
Description: Nutropin 0.1 mg/day self-administered once a day
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg
Description: GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Description: Caffeine will be available as oral tablets at unit dose strength of 200 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Description: Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Montelukast will be available as oral tablets at unit dose strength of 10 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Description: Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Description: Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg (2.5 mL)
Description: Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
Study NCT04425902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Description: Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
Study NCT02564679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve gastrectomy (LSG)
Description: These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated.
Study NCT02564679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment.
Study NCT00676000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted vaginal closure
Description: Horizontal mattress closure of vaginal mucosa over mesh
Study NCT00768430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
Study NCT00768430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single dose 0.045 mg/kg IV infused over 40 minutes
Study NCT02145325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded Tregs
Study NCT03078751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant endocrine therapy
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
Study NCT00676000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous vaginal closure
Description: Running closure of vaginal mucosa over mesh
Study NCT03078751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Description: Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
Study NCT03078751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth.
Study NCT02745314 — intervention group
Intervention type: OTHER
Intervention: Frailty measurement
Description: Frailty measurement under Fried at el criteria
Study NCT02745314 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Multidimensional Geriatric Assessment
Study NCT03525483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for renal resistivity index measurement
Description: Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ...
Study NCT02052609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827 140mg SC
Description: Experimental1:KHK4827 140mg subcutaneous injection
Study NCT02052609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827 210mg SC
Description: Experimental2:KHK4827 210mg subcutaneous injection
Study NCT04546607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuvastatic TM (C5OSEW5050ESA) 1000 mg
Description: Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
Study NCT04546607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nuvastatic TM (C5OSEW5050ESA) 1000 mg
Description: Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
Study NCT01296932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
Study NCT04906603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
Study NCT01096290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubiprostone
Description: 24mcg BID, capsule, oral 30days
Study NCT01096290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Twice daily for 30days, oral
Study NCT03092765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: Intravenous administration
Study NCT00462982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT03057262 — intervention group
Intervention type: DEVICE
Intervention: Repositioning splint
Description: Application of repositioning splint in the study group.
Study NCT02975271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant
Study NCT02975271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01530685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycabiane
Description: 2 gelule per day for 4 months
Study NCT01530685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 gelules per day for 4 months
Study NCT02796027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRIDGE
Description: BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs
Study NCT01915056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA-driven Intervention
Description: For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
Study NCT01362933 — intervention group
Intervention type: PROCEDURE
Intervention: VTE treatment in cancer patient description
Description: proportion of patients treated for evolutive VTE according to international recommendations
Study NCT04133181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D guide
Description: Use of a 3D guide in endodontic surgery
Study NCT04133181 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock guide
Description: Use of a mock guide in endodontic surgery
Study NCT02322528 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Administration of Lotemax
Description: An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
Study NCT03092765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration
Study NCT00059891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00059891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study NCT01066494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amonafide + cytarabine
Description: Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
Study NCT03465891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
Study NCT03465891 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low- Dose, Local Radiotherapy
Description: 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
Study NCT03222141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation of the THV Prosthesis
Description: Patients with TAVR implantation
Study NCT02042391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab sc
Description: All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
Study NCT01407588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic navigation
Description: Ablation with use of the magnetic navigation system
Study NCT01407588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation performed with manual navigation
Description: Atrial fibrillation ablation performed with manual navigation
Study NCT02857439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard diagnostic item list
Description: All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate
Description: In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin lactobionate
Description: In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-Spirulina
Description: The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [13C]-Spirulina
Description: The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [13C]-Spirulina
Description: The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin Ethylsuccinate Suspension
Description: In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
Study NCT02755064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Suspension
Description: In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
Study NCT02938169 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)
Study NCT02938169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: * stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)
Study NCT03263689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
Study NCT03263689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
Study NCT01592149 — intervention group
Intervention type: OTHER
Intervention: No Drug
Description: No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
Study NCT04309461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Control
Description: The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
Study NCT04309461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted MBC2 Program
Description: The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
Study NCT04586426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by subcutaneous (SC) injection.
Study NCT04586426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection.
Study NCT04586426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection.
Study NCT00981851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (Spiriva) + Salbutamol (Ventolin)
Description: 1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
Study NCT00981851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
Study NCT04403074 — intervention group
Intervention type: PROCEDURE
Intervention: Celiac Plexus Neurolysis
Description: When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
Study NCT00595985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT01847339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
Study NCT01847339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure